KR20160074116A - Cosmetic composition containing Crataegis fructus fermented extract - Google Patents
Cosmetic composition containing Crataegis fructus fermented extract Download PDFInfo
- Publication number
- KR20160074116A KR20160074116A KR1020140182953A KR20140182953A KR20160074116A KR 20160074116 A KR20160074116 A KR 20160074116A KR 1020140182953 A KR1020140182953 A KR 1020140182953A KR 20140182953 A KR20140182953 A KR 20140182953A KR 20160074116 A KR20160074116 A KR 20160074116A
- Authority
- KR
- South Korea
- Prior art keywords
- lactobacillus
- fermented
- extract
- skin
- cosmetic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000284 extract Substances 0.000 title claims abstract description 108
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 239000002537 cosmetic Substances 0.000 title claims abstract description 61
- 241000186660 Lactobacillus Species 0.000 claims abstract description 31
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 30
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 72
- 241000894006 Bacteria Species 0.000 claims description 39
- 235000014655 lactic acid Nutrition 0.000 claims description 36
- 239000004310 lactic acid Substances 0.000 claims description 36
- 238000000855 fermentation Methods 0.000 claims description 35
- 230000004151 fermentation Effects 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 24
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 21
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 18
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 18
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 17
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 16
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 13
- 230000002087 whitening effect Effects 0.000 claims description 13
- 230000037303 wrinkles Effects 0.000 claims description 12
- 230000003020 moisturizing effect Effects 0.000 claims description 11
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 10
- 239000002609 medium Substances 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 241001504592 Trachurus trachurus Species 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000009759 skin aging Effects 0.000 claims description 4
- 241001632410 Eleutherococcus senticosus Species 0.000 claims description 3
- 244000184734 Pyrus japonica Species 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 54
- 230000000694 effects Effects 0.000 abstract description 24
- 230000003078 antioxidant effect Effects 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 230000004663 cell proliferation Effects 0.000 abstract description 9
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 230000000968 intestinal effect Effects 0.000 abstract description 6
- 210000004927 skin cell Anatomy 0.000 abstract description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract description 5
- 235000013824 polyphenols Nutrition 0.000 abstract description 5
- 229930003935 flavonoid Natural products 0.000 abstract description 4
- 150000002215 flavonoids Chemical class 0.000 abstract description 4
- 235000017173 flavonoids Nutrition 0.000 abstract description 4
- 238000010828 elution Methods 0.000 abstract description 3
- 230000037330 wrinkle prevention Effects 0.000 abstract description 2
- 235000017159 Crataegus pinnatifida Nutrition 0.000 abstract 3
- 241000657480 Crataegus pinnatifida Species 0.000 abstract 3
- 230000000975 bioactive effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 21
- 239000006071 cream Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- -1 tracant Substances 0.000 description 11
- 241000257465 Echinoidea Species 0.000 description 10
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 9
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 241001608472 Bifidobacterium longum Species 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000304886 Bacilli Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 244000141359 Malus pumila Species 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- GTPUEIXKLQUDEJ-CSKARUKUSA-N (5-methyl-2-propan-2-ylphenyl) (e)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)OC=2C(=CC=C(C)C=2)C(C)C)=C1 GTPUEIXKLQUDEJ-CSKARUKUSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 235000014493 Crataegus Nutrition 0.000 description 1
- 241001092040 Crataegus Species 0.000 description 1
- 235000006922 Crataegus tracyi Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010017807 Gastric mucosal hypertrophy Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- MZNYWPRCVDMOJG-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine dihydrochloride Chemical compound [Cl-].[Cl-].C1=CC=C2C([NH2+]CC[NH3+])=CC=CC2=C1 MZNYWPRCVDMOJG-UHFFFAOYSA-N 0.000 description 1
- 101150005851 NOS gene Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 244000060616 Pseudosasa japonica var. japonica Species 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023118 Transcription factor JunD Human genes 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012599 radical scavenging assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 산사 발효 추출물의 제조방법 및 상기 발효 추출물을 함유하는 기능성 화장료 조성물에 관한 것이다. The present invention relates to a process for producing an acid fermentation extract and a functional cosmetic composition containing the fermentation extract.
산사는 생김새가 둥글고 붉으며, 흰색의 반점이 있다. 바깥면은 황갈색이나 회색을 띤 적갈색이며 많은 가는 주름이 있다. 한쪽에는 지름 5㎜의 오목하게 들어간 곳이 있고 그 주변에 가끔 꽃받침이 남아 있으며, 다른 한쪽에는 과병 또는 자국이 남아 있다. 옆으로 자른면에는 5실로 된 씨방이 있으며 각 방에는 1개의 씨가 들어 있다. 씨는 공을 몇 개로 등분한 모양으로 길이 6 ~ 8 mm이며 바깥면은 엷은 갈색이고 딱딱하며 질은 단단하다. 다른 이름으로 산사(酸査), 산리홍(山里紅), 홍과(紅果), 북산사(北山査), 적과자(赤瓜子), 산조홍(山棗紅), 홍과자(紅果子), 양구자(羊仇子), 당구자(棠子), 모사(茅), 산리과(山里果), 서사(鼠査), 서사(鼠), 양구(羊), 적조실(赤爪實), 후사(), 구자(子), 계매(梅)라고도 한다. Sansa is round and red in appearance, with white spots. Outer surface is yellowish brown or grayish reddish brown with many thin wrinkles. On one side there is a concave 5mm diameter, with occasional calyx around it, and on the other side there are scars or marks. On the side cut, there are 5 ovens with one seed in each room. The seeds are divided into several balls with a length of 6-8 mm, the outer surface is light brown, hard, and the quality is hard. Other names include Sansa, Sanri Hong, Red Pepper, Northern Sansa, Red Pepper, Sanzong Red, Red Pepper, Yanggu There are three kinds of characters: 羊 拳 子, billiard 棠 子, mosa, 羊 里 果, narrative, narrative, sheep, red 实, (), A child, and a plum (梅).
산사는 비위를 따뜻하게 하여 소화를 촉진하며 고기를 먹고 체했을 때 효과가 있고 복통, 설사, 위산과다, 만성장염 등에 사용한다. 또한 혈분에 작용하여 혈의 흐름을 돕고 어혈을 없애주며 약리작용으로 강심작용, 혈액순환개선, 혈압강하 등이 보고 되고 있다. 최근들어 산사에 들어 있는 폴리페놀이 피부암에 대한 예방 효과가 보고 되고 있으며, 항염증, 항산화 등의 효능도 알려져 있다. Sansa promotes digestion by warming the noodles. It is effective when it eats meat. It is used for abdominal pain, diarrhea, gastric hyperplasia, chronic enteritis. It also acts on the blood stream to help the flow of blood, eliminates the eosinophilia, and has been reported to have pharmacological actions such as arteriosclerosis, blood circulation improvement, and blood pressure reduction. Recently, polyphenols in Sansa have been reported to prevent skin cancer, and anti-inflammatory and antioxidant effects are known.
한편, 발효공학의 발달에 힘입어 발효에 의한 유효성분의 전환 및 함량증가, 발효과정에서 새로이 생성되는 물질에 관한 관심이 높아져 천연 소재를 발효시킬 수 있는 GRAS 균주의 산업적 이용에 대한 관심이 높아지고 있고 이로인해 장내 유산균의 분이 및 동정과 이를 이용한 허브나 식물소재 발효기술에 관한 연구 개발이 활발히 진행되고 있다. 하지만 발효공정을 응용하여 천연물을 발효시킨 국내 연구동향을 살펴본 결과 청국장 발효에 사용되는 고초균이나 장내 미생물인 락토바실러스나 비피더스 유산균등으로 사용균주들이 제한적이라는 한계가 있다. On the other hand, due to the development of fermentation engineering, there has been a growing interest in the industrial utilization of GRAS strains capable of fermenting natural materials, due to an increase in the conversion and content of active ingredients by fermentation, As a result, research and development on the fermentation technology of herbs and plant materials using the fraction and identification of lactic acid bacteria in the intestines have been actively carried out. However, as a result of investigating the domestic research trend of fermenting natural products by applying the fermentation process, there are limitations that the strains used are limited to lactobacillus or bifidus lactic acid bacteria, such as Bacillus subtilis and intestinal microorganisms used for fermenting chungkukjang.
이에 본 발명자들은 인체에서 분리한 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)로 이루어진 군에서 선택된 1종 이상의 유산균을 이용하여 산사를 발효 추출하였을 때 세포 증식 촉진, 항산화 효능, 주름 방지 및 피부 보습력 개선 효과 등이 있어 화장료 조성물로 사용 적합함을 확인함으로써 본 발명을 완성하였다. Accordingly, the present inventors have found that a mutant strain selected from the group consisting of Lactobacillus ramnosus HK-9 KCCM11254P, Lactobacillus acidophilus and Lactobacillus bulgaricus isolated from the human body The present invention has been accomplished by confirming that it is suitable for use as a cosmetic composition because it promotes cell proliferation, antioxidant efficacy, wrinkle prevention, and skin moisturizing effect when fermented with the above-mentioned lactic acid bacteria.
따라서 본 발명의 목적은 (a) 고압 멸균기에 의해 멸균된 배지에 유산균을 3 ~ 7%(v/v)의 농도로 접종하여 34 ~ 40℃의 온도에서 12 ~ 36시간동안 혐기배양하는 단계; (b) 상기 (a)단계에서 유산균이 배양된 배지에 건조된 산사와 배양 배지의 양을 전체 배양배지 중량 대비 1:8 ~ 1:12의 비율로 혐기 배양하여 산사의 발효물을 제조하는 단계; (c) 상기 (b)단계에서 얻어진 산사의 발효액을 따로 모아두고 남은 건체 산사의 발효물을 전체 배양배지 중량 대비 1:8 ~ 1:12의 비율로 준비하고, 70% 에탄올을 이용하여 50 ~ 70℃의 온도에서 20 ~ 28시간동안 진탕추출을 한 후 추출물을 여과지로 여과하여 산사의 추출물을 제조하는 단계; 및 (d) 상기 (b)단계에서 얻어진 산사의 발효물과 (c)단계에서 얻어진 산사의 추출물을 혼합하는 단계;를 포함하는 산사 발효 추출물 제조방법을 제공하는 것이다. Therefore, an object of the present invention is to (a) anaerobically culturing lactic acid bacteria at a concentration of 3-7% (v / v) at a temperature of 34-40 ° C for 12-36 hours in a medium sterilized by a high pressure sterilizer; (b) anaerobically culturing the fermented product in an amount of 1: 8 to 1:12 based on the total weight of the culture medium and culturing the fermented product in the step (a) ; (c) The fermented broodstock fermented from the step (b) is separately collected, and the remaining fermented broodstock is prepared at a ratio of 1: 8 to 1:12 with respect to the total culture medium weight. Extracting the extract with shaking at a temperature of 70 ° C for 20 to 28 hours, filtering the extract with a filter paper to prepare an extract of Acanthopanax senticosus; And (d) mixing the fermented product of the horse mackerel obtained in the step (b) with the extract of the horse mackerel obtained in the step (c).
본 발명의 다른 목적은 상기 본 발명의 방법으로 제조된 산사 발효 추출물을 유효성분으로 포함하는 화장료 조성물을 제공하는 것이다. It is another object of the present invention to provide a cosmetic composition comprising the fermented sea urchin fermentation extract prepared by the method of the present invention as an active ingredient.
본 발명의 다른 목적은 산사 발효 추출물을 유효성분으로 포함하는 피부 노화 방지용 화장료 조성물을 제공하는 것이다. It is another object of the present invention to provide a cosmetic composition for preventing skin aging which comprises an acid-fast bacilli extract as an active ingredient.
본 발명의 다른 목적은 산사 발효 추출물을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공하는 것이다. Another object of the present invention is to provide a cosmetic composition for skin whitening comprising an acid-fast fermented extract as an active ingredient.
본 발명의 다른 목적은 산사 발효 추출물을 유효성분으로 포함하는 피부 주름 개선용 화장료 조성물을 제공하는 것이다. Another object of the present invention is to provide a cosmetic composition for improving skin wrinkles comprising an acid-licensed fermented extract as an active ingredient.
나아가 본 발명의 목적은 산사 발효 추출물을 유효성분으로 포함하는 피부 항염 효과 또는 피부 보습 효과를 가지는 화장료 조성물을 제공하는 것이다. It is still another object of the present invention to provide a cosmetic composition having a skin anti-inflammatory effect or a skin moisturizing effect, which comprises an acid-fast bacilli extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 (a) 고압 멸균기에 의해 멸균된 배지에 유산균을 3 ~ 7%(v/v)의 농도로 접종하여 34 ~ 40℃의 온도에서 12 ~ 36시간동안 혐기배양하는 단계; (b) 상기 (a)단계에서 유산균이 배양된 배지에 건조된 산사와 배양 배지의 양을 전체 배양배지 중량 대비 1:8 ~ 1:12의 비율로 혐기 배양하여 산사의 발효물을 제조하는 단계; (c) 상기 (b)단계에서 얻어진 산사의 발효액을 따로 모아두고 남은 건체 산사의 발효물을 전체 배양배지 중량 대비 1:8 ~ 1:12의 비율로 준비하고, 70% 에탄올을 이용하여 50 ~ 70℃의 온도에서 20 ~ 28시간동안 진탕추출을 한 후 추출물을 여과지로 여과하여 산사의 추출물을 제조하는 단계; 및 (d) 상기 (b)단계에서 얻어진 산사의 발효물과 (c)단계에서 얻어진 산사의 추출물을 혼합하는 단계;를 포함하는 산사 발효 추출물 제조방법을 제공한다. In order to accomplish the above object, the present invention provides a method for producing a microorganism, which comprises (a) inoculating a microbial strain sterilized with a high pressure sterilizer at a concentration of 3-7% (v / v) Culturing; (b) anaerobically culturing the fermented product in an amount of 1: 8 to 1:12 based on the total weight of the culture medium and culturing the fermented product in the step (a) ; (c) The fermented broodstock fermented from the step (b) is separately collected, and the remaining fermented broodstock is prepared at a ratio of 1: 8 to 1:12 with respect to the total culture medium weight. Extracting the extract with shaking at a temperature of 70 ° C for 20 to 28 hours, filtering the extract with a filter paper to prepare an extract of Acanthopanax senticosus; And (d) mixing the fermented product of the horse mackerel obtained in the step (b) with the extract of the horse mackerel obtained in the step (c).
본 발명의 일실시예에 있어서, 상기 (a)단계의 유산균은 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)로 이루어진 군에서 선택된 1종 이상일 수 있다. In one embodiment of the present invention, the lactic acid bacterium of step (a) is selected from the group consisting of Lactobacillus ramnosus HK-9, KCCM11254P, Lactobacillus acidophilus , and Lactobacillus bulgaricus ) may be used.
본 발명은 상기 방법으로 제조된 산사 발효 추출물을 유효성분으로 포함하는 화장료 조성물을 제공한다. The present invention provides a cosmetic composition comprising the granular extract obtained by the above method as an active ingredient.
또한, 본 발명은 산사 발효 추출물을 유효성분으로 포함하는 피부 노화 방지용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for preventing skin aging comprising an acid-fast fermented extract as an active ingredient.
본 발명의 일실시예에 있어서, 상기 산사 발효 추출물은 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)로 이루어진 군에서 선택된 1종 이상일 수 있다. In one embodiment of the present invention, the fermented sea urchin fermentation extract is selected from the group consisting of Lactobacillus ramnosus HK-9 KCCM11254P, Lactobacillus acidophilus and Lactobacillus bulgaricus And may be at least one selected from the group consisting of
또한, 본 발명은 산사 발효 추출물을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for skin whitening comprising an acid-fast fermented extract as an active ingredient.
본 발명의 일실시예에 있어서, 상기 산사 발효 추출물은 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)로 이루어진 군에서 선택된 1종 이상일 수 있다. In one embodiment of the present invention, the fermented sea urchin fermentation extract is selected from the group consisting of Lactobacillus ramnosus HK-9 KCCM11254P, Lactobacillus acidophilus and Lactobacillus bulgaricus And may be at least one selected from the group consisting of
또한, 본 발명은 산사 발효 추출물을 유효성분으로 포함하는 피부 주름 개선용 화장료 조성물을 제공한다. The present invention also provides a cosmetic composition for improving skin wrinkles comprising an acid-fast berry extract as an active ingredient.
본 발명의 일실시예에 있어서, 상기 산사 발효 추출물은 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)로 이루어진 군에서 선택된 1종 이상일 수 있다. In one embodiment of the present invention, the fermented sea urchin fermentation extract is selected from the group consisting of Lactobacillus ramnosus HK-9 KCCM11254P, Lactobacillus acidophilus and Lactobacillus bulgaricus And may be at least one selected from the group consisting of
나아가 본 발명은 산사 발효 추출물을 유효성분으로 포함하는 피부 항염 효과 또는 피부 보습 효과를 가지는 화장료 조성물을 제공한다. Further, the present invention provides a cosmetic composition having a skin anti-inflammatory effect or a skin moisturizing effect comprising an acid-fast bacilli extract as an active ingredient.
본 발명의 일실시예에 있어서, 상기 산사 발효 추출물은 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)로 이루어진 군에서 선택된 1종 이상일 수 있다. In one embodiment of the present invention, the fermented sea urchin fermentation extract is selected from the group consisting of Lactobacillus ramnosus HK-9 KCCM11254P, Lactobacillus acidophilus and Lactobacillus bulgaricus And may be at least one selected from the group consisting of
본 발명은 산사 발효 추출물의 제조방법 및 상기 산사 발효 추출물을 유효성분으로 포함하는 화장료 조성물에 관한 것으로서, 본 발명의 화장료 조성물은 산사를 피부유래 발효 유산균주 및 장내 유산균을 이용하여 발효하고 추출함으로써 산사에 함유되어 있는 폴리페놀, 플라보노이드 등의 유효 생리활성 성분의 용출을 증진하여 항산화능을 향상시키며, 피부 항염, 피부 세포의 증식 촉진, 주름 방지, 피부 보습 및 피부 미백의 효과가 있다. The present invention relates to a method for producing an acid fermentation extract and a cosmetic composition comprising the acid fermentation extract as an active ingredient, wherein the cosmetic composition of the present invention ferments and extracts the sea lye using the skin-derived fermented lactic acid bacteria and the intestinal lactic acid bacteria, And enhances the antioxidant ability by promoting dissolution of effective physiologically active ingredients such as polyphenols and flavonoids contained in the skin, and has effects of skin anti-inflammation, promotion of proliferation of skin cells, prevention of wrinkles, skin moisturization and skin whitening.
도 1은 다양한 유산균으로 발효한 산사 발효 추출물의 DPPH 소거 활성을 측정한 그래프이다.
도 2는 UVA가 조사된 CCD-986sk 세포에서의 다양한 유산균으로 발효한 산사 발효 추출물의 MMP-1 발현 저해율에 대한 그래프이다.
도 3은 다양한 유산균으로 발효한 산사 발효 추출물의 멜라닌 합성 저해율을 측정한 그래프이다.
도 4는 다양한 유산균으로 발효한 산사 발효 추출물의 산화질소(NO) 생성량을 측정한 결과이다. FIG. 1 is a graph showing DPPH scavenging activity of a fermented sea urchin fermented extract fermented with various lactic acid bacteria.
FIG. 2 is a graph showing the inhibition rate of MMP-1 expression of the acid fermentation extract fermented with various lactic acid bacteria in CCD-986sk cells irradiated with UVA.
FIG. 3 is a graph showing melanin synthesis inhibition rates of the fermented Sansafura fermentation extract fermented with various lactic acid bacteria.
FIG. 4 shows the results of measurement of the amount of nitrogen oxides (NO) produced by fermented extracts of various fermented lactic acid bacteria.
본 발명은 산사 발효 추출물의 제조방법 및 상기 산사 발효 추출물을 유효성분으로 포함하는 화장료 조성물을 제공함에 그 특징이 있다. The present invention is characterized by providing a process for producing an acid fermentation extract and a cosmetic composition comprising the acid fermentation extract as an active ingredient.
최근 많은 여성들뿐만 아니라 남성의 경우에도 미용에 대한 관심이 급증하면서 피부미백, 여드름, 아토피 피부염 및 주름 개선을 위한 다양한 기능성 화장품들이 출시되고 있다. 그러나 시중에 판매되고 있는 대부분의 기능성 화장품의 경우, 합성 화합물을 사용한 제품들이 대부분인데 합성화합물이 첨가된 화장품은 피부에 따라 민감한 피부반응을 유발시킬 수 있어, 다양한 피부 부작용을 초래하는 문제점이 있다. In recent years, not only many women but also men have become increasingly interested in cosmetics, and various functional cosmetics for skin whitening, acne, atopic dermatitis and wrinkle are being released. However, most functional cosmetics sold on the market are products using synthetic compounds, and cosmetic products containing synthetic compounds can cause sensitive skin reactions depending on the skin, which causes various skin side effects.
이에 본 발명자들은 부작용이 없고 비용이 저렴하여 안정성이 우수한 기능성 화장료 제조를 위하여 연구하고 있던 중 유산균 및 산사에 주목하였다. Accordingly, the present inventors paid attention to lactic acid bacteria and sasanghae which were studied for the production of functional cosmetics having no side effects and low cost and excellent stability.
유산균은 전 세계적으로 광범위하게 이용 및 응용되는 중요한 미생물이며 치즈, 발효유 및 유산균 음료 등의 발효 유제품과 김치, 청국장과 같은 식품산업에 오랫동안 사용되어 왔다. 유산균은 예로부터 장 질환에 대한 치료 및 예방의 정장효과를 가지고 있어 장내 유해균의 증식을 막고, 유익한 균의 생장에 좋은 조건을 만들어 주어 식중독 방지, 장내 부패방지, 변비예방, 발암 억제, 면역력의 증가 등의 여러 가지 생리활성을 가진다고 알려져 있어 다양한 유제품, 식품 및 화장품산업에 사용되고 있다. Lactic acid bacteria are important microorganisms widely used and applied worldwide, and they have been used for a long time in fermented dairy products such as cheese, fermented milk and lactic acid bacteria drink, and food industry such as kimchi and chungkukjang. Lactobacillus has a long-lasting effect on the treatment and prevention of intestinal diseases, thus preventing the growth of harmful bacteria in the intestines and making good conditions for the growth of beneficial bacteria, thereby preventing food poisoning, preventing intestinal decline, preventing constipation, And is used in various dairy products, foods, and cosmetics industries.
또한, ‘산사’는 장미과 사과나무속에 속하는 소교목인 산사나무 열매를 산사 또는 산사자라고 하며, 아시아와 북아메리카가 원산지이고 흔히 심는 사과나무보다는 딱딱하고 훨씬 작으며 가시가 있다. 맛은 시큼하지만 색깔이 선명하고 적당한 단맛도 가지고 있어 젤리, 통조림, 술, 차로 만들어 먹었으며 한방에서는 생약을 위장약 등으로 이용하였다. In addition, 'Sansa' is a small species belonging to the Rosaceae apple tree, which is called horsetail or mountain hawthorn. It is hard and much smaller than thorny apple tree and has thorns. It is originated in Asia and North America. The taste is sour, but it has a clear color and moderate sweetness, and it is made with jelly, canned food, alcohol and tea. In herbal medicine, herbal medicine is used as a gastrointestinal medicine.
산사는 고기를 먹고 체한 데에 효험이 있으며 고혈압, 심장병, 소화불량과 고지혈증 치료에 특히 좋은 효능이 있다고 알려져 있다. Sansa is effective in eating meat, and is known to have a particularly good efficacy in the treatment of hypertension, heart disease, indigestion and hyperlipidemia.
본 발명자들은 부작용이 없고 비용이 저렴하여 안정성이 우수한 기능성 화장료 제조를 위하여 연구하고 있던 중 산사를 피부유래 유산균인 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P와 장내 유산균인 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)를 이용하여 발효 추출 시 산사에 함유되어 있는 폴리페놀, 플라보노이드 등의 유효 생리활성 성분의 용출을 증진하여 항산화능을 향상시키며, 피부 항염, 피부 세포의 증식 촉진, 주름 방지, 피부 보습 및 피부 미백의 효과가 있어 화장료 조성물로 사용하기 적합함을 처음으로 규명하였다는 점에 특징이 있다. The inventors of the Crataegus skin-derived lactic acid bacteria of the study were for the functional cosmetic composition having excellent production stability and low cost without the side effects Lactobacillus ramno suspension HK-9 (Lactobacillus Ramnosus HK-9) KCCM11254P and Lactobacillus acidophilus Lactobacillus acidophilus and Lactobacillus bulgaricus to improve the antioxidant activity by promoting the elution of effective physiologically active ingredients such as polyphenols and flavonoids contained in spermatozoa during fermentation extraction, Promoting, preventing wrinkles, skin moisturizing, and skin whitening, and is therefore suitable for use as a cosmetic composition.
본 발명의 일실시예에 따르면, 다양한 유산균으로 발효된 본 발명의 산사 발효 추출물의 피부 세포 증식 효과를 확인한 결과, 산사 발효 추출물을 처리하지 않은 대조군과 비교하여, 산사 발효 추출물 모든 실험군에서 60% 이상의 높은 섬유아세포 증식 효과를 나타냈으며 그 중 피부유래 유산균인 HK-9을 이용한 산사 발효추출물이 80.9%의 가장 높은 증식 효과를 보임을 알 수 있었다(표 7 참조).According to one embodiment of the present invention, the skin cell proliferation effect of the granular extract of the present invention fermented with various lactic acid bacteria was examined. As a result, compared with the control group not treated with the granular extract, The highest proliferation effect was obtained by the fermented extract of horseshoe crab using HK-9, which is a skin-derived lactic acid bacterium, 80.9% (see Table 7).
다른 일실시예 따르면, 본 발명의 방법으로 제조된 산사 발효 추출물의 항산화 활성 검증을 위해 DPPH (1,1-diphenyl-2-picrylhydrazyl) 라디칼 소거능 측정을 한 결과, 다양한 유산균으로 발효된 산사 발효 추출물 모두에서 농도가 증가할수록 DPPH 라디칼 소거능 수치가 증가하는 경향을 나타냈으며, 최고 농도인 1000㎍/ml의 농도에서 70% 이상의 높은 소거능을 나타내었다. 그 중 피부유래 유산균인 HK-9을 이용한 산사 발효 추출물의 소거능은 93.19%로 나타나 항산화 활성이 탁월하다는 것을 알 수 있었다(도 1 참조).According to another embodiment, DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity was measured for the antioxidative activity of the fermented extract of Sansafura prepared by the method of the present invention. As a result, , The DPPH radical scavenging activity tended to increase with increasing concentration, and showed a high scavenging activity of over 70% at the highest concentration of 1000 μg / ml. Among them, the scavenging ability of the fermented sea tangle extract using HK-9, which is a skin-derived lactic acid bacterium, was 93.19%, indicating that the antioxidant activity was excellent (see FIG. 1).
다른 일실시예 따르면, 본 발명의 방법으로 제조된 산사 발효 추출물에 보습 효과가 있는지를 알아보기 위해 Collagen type I 생성량을 측정한 결과, 산사 발효 추출물의 첨가를 통해 모든 조건의 콜라겐 생성량이 농도 의존적으로 증가하는 경향을 나타내었으며, 1.0 mg/mL의 양성 대조군(아스코르브산)에 비해 높은 콜라겐 합성량을 나타냄을 알 수 있었다(표 8 참조).According to another embodiment, in order to investigate the moisturizing effect of the fermented sea tangle extract prepared by the method of the present invention, the amount of collagen type I produced was measured, (Ascorbic acid) as compared with the positive control (1.0 mg / mL) (see Table 8).
다른 일실시예 따르면, 본 발명의 방법으로 제조된 산사 발효 추출물에 주름을 억제하는 효과가 있는지를 알아보기 위하여 사람의 섬유아세포인 CCD-986sk에 UV 조사한 후 다양한 처리군에 따른 MMP-1 발현 저해 효과를 ELISA로 측정한 결과, 산사 발효 추출물에서 농도 의존적으로 MMP-1 발현 저해율이 높아져 최고 농도인 1 mg/mL에서 산사 발효 추출물을 대조군과 비교하여 각각 일반 산사 추출물은 60.15%, HK-9를 이용한 산사 발효 추출물은 69.55%, L. bulgaricus를 이용한 산사 발효 추출물은 64.02%, B. longum을 이용한 산사 발효 추출물은 35.81%의 저해율을 나타낸 것으로 보아 본 발명의 산사 발효 추출물은 MMP-1의 발현을 효과적으로 조절하여 주름 발현을 저해함을 알 수 있었다(도 2 참조).According to another embodiment, in order to investigate the effect of suppressing the wrinkle on the fermented extract of Sansafura prepared by the method of the present invention, the human fibroblast CCD-986sk was UV-irradiated and then the inhibition of MMP-1 expression As a result of the ELISA, the inhibition rate of MMP-1 expression was increased in a concentration-dependent manner in the acid fermentation extract, and the highest concentration of 1 mg / mL was 60.15%, HK-9 As a result, the inhibition rate of MCP-1 expression by the present invention was 69.55%, that of L. bulgaricus was 64.02%, that of L. bulgaricus was 64.02%, and that of B. longum was 35.81% And effectively suppressed the appearance of wrinkles (see FIG. 2).
다른 일실시예 따르면, 본 발명의 방법으로 제조된 산사 발효 추출물에 피부 미백 효과가 있는지를 알아보기 위하여 멜라닌을 생성하는 쥐 유래 멜라노사이트(melanocyte)인 Clone-M3를 이용하여 멜라닌 생성량을 측정한 결과, 산사 발효 추출물의 농도가 증가할수록 멜라닌 합성 저해율이 높아지는 것을 확인할 수 있었으며, 최고농도인 100 ㎍/㎖에서 각각 일반 산사 추출물은 34.11%, HK-9를 이용한 산사 발효 추출물은 41.21%, L. bulgaricus를 이용한 산사 발효 추출물은 35.87%, B. longum을 이용한 산사 발효 추출물은 36.99%로 나타났다(도 3 참조).According to another embodiment, melanin production was measured using Clone-M3, a melanocyte-producing melanocyte which produces melanin, in order to investigate whether skin-whitening effect produced by the method of the present invention is skin-whitening effect , The inhibition rate of melanin synthesis was increased as the concentration of fermented soybean curd extract increased. In the highest concentration of 100 ㎍ / ㎖, 34.11% of general crustacean, HK - 9, 41.21% of L. bulgaricus (35.87%) and B. longum (36.3%), respectively (see FIG. 3).
다른 일실시예 따르면, 본 발명의 방법으로 제조된 산사 발효 추출물에 항염 활성이 있는지를 확인하기 위하여 마크로파지(Macrophage)를 이용하여 nitric oxide(NO) 생성량을 측정한 결과, 시료를 단독 투여한 경우 대조군과 비교하여 큰 차이를 보이지 않았으나 LPS와 함께 처리할 경우, LPS를 단독으로 처리한 4.2 μM보다, 월등히 높은 NO 생성량을 보이며, 특히 피부유래 유산균인 HK-9을 이용한 본 발명의 산사 발효 추출물의 경우 10.5 μM로써 높은 NO 생성량을 보여 뛰어난 항염 활성을 보임을 알 수 있었다(도 4 참조).According to another embodiment of the present invention, the amount of nitric oxide (NO) produced by macrophage was measured in order to confirm the anti-inflammatory activity of the fermented extract produced by the method of the present invention. As a result, . However, the treatment with LPS showed significantly higher NO production than the treatment with LPS alone (4.2 μM). In particular, in the case of the acid fermentation extract of the present invention using the skin-derived lactic acid bacterium HK-9 10 < 5 > .mu.M, indicating an excellent anti-inflammatory activity (see FIG. 4).
따라서 이러한 결과를 토대로 본 발명의 방법으로 제조된 산사 발효 추출물은 산사에 함유되어 있는 폴리페놀, 플라보노이드 등의 유효 생리활성 성분의 용출을 증진하여 항산화능을 향상시키며, 피부 항염, 피부 세포의 증식 촉진, 주름 방지, 피부 보습 및 피부 미백의 효과가 우수하므로 기능성 화장료 조성물로 사용할 수 있다. Therefore, based on these results, the Sansa fermented extract prepared by the method of the present invention improves the antioxidant ability by promoting the elution of effective physiologically active ingredients such as polyphenols and flavonoids contained in sasan, and promotes skin inflammation, promotion of skin cell proliferation , Anti-wrinkle, skin moisturizing and whitening effect, so that it can be used as a functional cosmetic composition.
본 발명의 산사에 발효를 위해 사용된 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 또는 락토바실러스 불가리커스(Lactobacillus bulgaricus)의 균주는 화장료 조성물 총 중량에 대하여 0.001 ~ 20 중량%로 첨가할 수 있다. Lactobacillus Lymphosus HK-9 ( Lactobacillus < RTI ID = 0.0 > Ramnosus HK-9) KCCM11254P, Lactobacillus ( Lactobacillus acidophilus or Lactobacillus bulgaricus may be added in an amount of 0.001 to 20% by weight based on the total weight of the cosmetic composition.
상기 균주를 화장료 총 중량에 대해 0.001 중량% 미만으로 첨가하는 경우에는 본 발명의 화장료 조성물이 가지는 다양한 생리활성 효과를 나타내지 않으며, 반면 20 중량%를 초과하여 첨가될 경우에는 세포 등에 독성으로 작용하거나 또는 목적하는 효과를 첨가량에 비례하여 얻지 못하기 때문에 경제성을 고려하여 상기 기술된 범위 이내의 함량으로 첨가하는 것이 바람직하며, 또한 첨가량에 따른 화장료 조성물 가격이 상승되므로 경제적이지 못한 문제점이 있다.When the above-mentioned strain is added in an amount of less than 0.001% by weight based on the total weight of the cosmetic, the cosmetic composition of the present invention does not exhibit various physiological activity effects. On the other hand, when added in an amount exceeding 20% by weight, The desired effect can not be obtained in proportion to the added amount. Therefore, it is preferable to add the cosmetic composition within the above-described range in consideration of economical efficiency, and the cost of the cosmetic composition according to the amount of the cosmetic composition increases.
본 발명의 산사 발효 추출물이 화장료 조성물로 제조되는 경우, 본 발명의 조성물은 상술한 산사를 발효 및 추출할 뿐만 아니라, 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함할 수 있다.When the fermented extract of the present invention is prepared by a cosmetic composition, the composition of the present invention may include not only fermentation and extraction of the above-mentioned persimmon but also components commonly used in cosmetic compositions. Examples thereof include antioxidants, , Customary adjuvants such as solubilizers, vitamins, pigments and flavoring agents, and carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, a mixture of chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters.
또한, 본 발명은 본 발명의 화장료 조성물을 인간의 피부에 도포하는 것을 특징으로 하는 화장방법을 제공한다.The present invention also provides a cosmetic method characterized by applying the cosmetic composition of the present invention to human skin.
본 발명의 화장 방법은 본 발명의 화장료 조성물을 인간의 피부에 도포하는 모든 화장 방법을 일컫는다. 즉, 화장료 조성물을 피부에 도포하는 당업계에 공지된 모든 방법이 본 발명의 화장 방법에 속한다.The cosmetic process of the present invention refers to all the cosmetic processes for applying the cosmetic composition of the present invention to human skin. That is, all methods known in the art for applying the cosmetic composition to the skin belong to the cosmetic method of the present invention.
본 발명의 화장료 조성물은 단독 또는 중복 도포하여 사용하거나, 본 발명 이외의 다른 화장료 조성물과 중복 도포하여 사용할 수 있다. 또한 본 발명에 따른 피부 주름 개선 효과가 우수한 화장료 조성물은 통상적인 사용방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.The cosmetic composition of the present invention may be used alone or in combination, or may be used by overlapping with other cosmetic compositions other than the present invention. Further, the cosmetic composition having excellent skin wrinkle-improving effect according to the present invention can be used according to a conventional method of use, and the use frequency of the cosmetic composition can be changed according to a user's skin condition or taste.
본 발명의 화장료 조성물이 비누, 계면활성제 함유 클렌징 또는 계면활성제 비함유 클렌징 제형일 경우, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 구체적인 예로서, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 함유 클린징 제형은 클렌징폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 겔이며, 이에 한정되는 것은 아니다.
When the cosmetic composition of the present invention is a soap, a surfactant-containing cleansing agent, or a surfactant-free cleansing agent, it may be applied to the skin and then wiped off or removed or washed with water. The surfactant-containing cleansing formulation is a cleansing foam, a cleansing water, a cleansing towel, and a cleansing pack. The surfactant-free cleansing formulation may be a cleansing cream, , Cleansing lotion, cleansing water and cleansing gel, but is not limited thereto.
이하 본 발명을 실시예에 의하여 더욱 상세하게 설명한다. 이들 실시예는 단지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It will be apparent to those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited to these embodiments.
<< 실시예Example 1> 1>
피부유래Derived from skin 유산균 및 일반 장내 유산균을 이용한 산사의 The use of lactic acid bacteria and common intestinal lactic acid bacteria 발효물Fermentation product 제조 Produce
본 발명의 산사 추출 부산물을 발효하기 위해 유산균을 MRS 배지에 배양하였다. 배양 방법은 일반적인 유산균 배양 방법으로 55%의 MRS 배지와 0.5%의 L-시스테인 하이드로클로라이드(L-Cysteine hydrochloride)를 첨가하여 배지를 제작 하였으며, 배양 온도는 37℃에서 배양 하였고 밀봉된 형태로 발효 균주 특성상 혐기성 조건에서 실험을 하여야 하기 때문에 최소한의 교반속도(50~60 rpm)로 배양하여 72시간동안 2L의 플라스크에서 1L 의 부피로 실험을 하였다. Lactic acid bacteria were cultured in MRS medium to ferment the by-products of the present invention. The culture medium was prepared by adding 55% of MRS medium and 0.5% of L-cysteine hydrochloride to the culture medium. The incubation temperature was 37 ° C, and the fermentation broth In order to conduct experiments under anaerobic conditions due to their characteristics, they were cultivated at a minimum stirring speed (50 to 60 rpm) and then subjected to a 1 L volume in a 2 L flask for 72 hours.
본 발명에서는 락토바실러스 람노서스 HK-9 KCCM11254P(Lactobacillus rhamnosus HK-9)와 대표적 일반 장내 유산균인 락토바실러스 불가리커스 (Lactobacillus bulgaricus), 비피도박테리아 롱검(Bifidobacterium Longum)을 사용하여 고압 멸균기에 의해 완전 멸균된 배지에 5%의 농도로 접종을 하여 37℃에서 48시간 동안 배양하여 발효를 진행하였다. 또한, 본 발명에서 사용한 산사는 수분을 7% 미만으로 포함하고 있는 건조된 산사을 사용하였다. In the present invention, Lactobacillus lambosus HK-9 KCCM11254P ( Lactobacillus rhamnosus HK-9) and the representative general intestinal lactobacillus Lactobacillus ( Lactobacillus bulgaricus ), Bifidobacterium Longum ) was inoculated at a concentration of 5% in a completely sterilized medium by a high-pressure sterilizer and cultured at 37 ° C for 48 hours to perform fermentation. In addition, the dried horseshoe used in the present invention was dried horseshoe containing less than 7% water.
산사와 상기 미생물이 처리된 배양 배지의 양은 전체 중량대비 1:1O의 비율로 배양을 하였으며, 발효가 끝나고 얻어진 발효액을 따로 모아두고 남은 건체 산사 발효물은 전체 중량대비 1:10의 비율로 70%에탄올을 이용하여 60℃에서 24시간 동안 진탕 추출을 하였다. 상기의 얻어진 산사 발효물을 추출한 추출물을 함께 감압 농축과 동결건조를 통해 파우더 형태로 제조하였다. The amount of the culture medium and the culture medium treated with the microorganism were cultured at a ratio of 1: 1 by weight to the total weight. After the fermentation, the fermented broth was collected, Ethanol was used for shaking extraction at 60 DEG C for 24 hours. The obtained extract obtained by extracting the fermented sea tangle was simultaneously subjected to concentration under reduced pressure and lyophilization to prepare a powder.
산사의 발효가 끝나고 얻어진 발효액을 따로 모아두고 남은 건체 산사 발효물에 70% 에탄올을 이용하여 1:10 (발효물:에탄올)로 첨가하여 60℃에서 24시간 동안 진탕 추출한 추출물을 여과지로 여과하여 남은 산사 슬러지를 제거한 다음, 여액을 감압농축과 동결과정을 거쳐 파우더 형태로 제조하여 발효물 파우더와 혼합하였다. 일반 산사의 경우 10배수의 70%에탄올을 첨가하여 상기 추출 및 여과, 감압농축, 동결과정과 동일하게 진행 하였다.
After fermentation, the obtained fermentation broth was collected, and the remaining fermented product was added to the dried fermented product at a ratio of 1:10 (fermented product: ethanol) using 70% ethanol. The extract was shaken at 60 ° C for 24 hours, After removing the sludge sludge, the filtrate was concentrated under reduced pressure and frozen to prepare powder form and mixed with the fermented powder. In the case of general hunting, 10% of 70% ethanol was added to perform the above extraction, filtration, concentration under reduced pressure, and freezing.
<< 실시예Example 2> 2>
본 발명의 The 산사추출물Sansa extract 및 발효 추출물을 함유하는 And fermented extract 화장료Cosmetics 조성물 제조방법 Method of manufacturing composition
본 발명자들은 상기 실시예 1의 방법으로 제조된 산사의 발효추출물을 포함한 화장료 조성물을 하기 표 1의 조성으로 제조하였으며, 본 발명의 락토바실러스 람노서스 HK-9 KCCM11254P(Lactobacillus rhamnosus HK-9)를 이용하여 발효된 산사 발효 추출물이 함유된 화장료 조성물의 효능과 비교하기 위하여 대조군으로서 표 1의 조성에서 산사의 발효추출물을 제외한 나머지 성분만으로 화장료 조성물을 제조하였다.
The inventors of the present invention prepared the cosmetic composition containing the fermented extract of Sansafura prepared by the method of Example 1 with the composition shown in Table 1 below and used Lactobacillus rhamnosus HK-9 of the present invention Lactobacillus lambosus HK-9 KCCM11254P In order to compare the efficacy of the cosmetic composition containing the fermented Sansafura fermented extract, the cosmetic composition was prepared using only the components other than the fermented extract of Sansha as the control group in Table 1.
이하 본 발명에 따른 피부유래 유산균인 HK-9을 이용한 산사 발효 추출물을 함유하는 화장료 조성물의 여러 제형예를 제시한다. 그러나 본 발명이 이에 한정되는 것은 아니다.
Hereinafter, various formulation examples of a cosmetic composition containing a fermented sea tangle extract using HK-9 as a skin-derived lactic acid bacterium according to the present invention are presented. However, the present invention is not limited thereto.
<2-1> <2-1> 유연화장수(Softening longevity skinskin ))
하기 표 2와 같은 조성으로 통상적인 유연화장수 제조방법에 의하여 제조된 본 발명의 피부유래 유산균인 HK-9을 이용한 산사 발효 추출물을 함유하는 유연화장수를 제조하였다.
The softened longevity water containing the fermented sea tangle extract of HK-9, which is the skin-derived lactic acid bacterium of the present invention prepared by a conventional method for producing softened longevity, was prepared as shown in Table 2 below.
<2-2> <2-2> 영양화장수(Nutrition lotion ( lotionlotion ))
하기 표 3과 같은 조성으로 통상적인 영양화장수 제조방법에 의하여 제조된 본 발명의 피부유래 유산균인 HK-9을 이용한 산사 발효 추출물을 함유하는 영양화장수를 제조하였다. Nutritional lotion containing the fermented sea tangle extract using the skin-derived lactic acid bacterium HK-9 of the present invention produced by a conventional method of producing a nutritive lotion with the composition shown in Table 3 below was prepared.
<2-3> <2-3> 영양크림Nourishing cream
하기 표 4와 같은 조성으로 통상적인 영양크림 제조방법에 의하여 제조된 본 발명의 피부유래 유산균인 HK-9을 이용한 산사 발효 추출물을 함유하는 영양크림을 제조하였다.
Nutritive creams containing the fermented sea tangle extract using the skin-derived lactic acid bacterium HK-9 of the present invention produced by the conventional nutrition cream preparation method as shown in Table 4 below were prepared.
<2-4> <2-4> 마사지크림Massage cream
하기 표 5와 같은 조성으로 통상적인 마사지크림 제조방법에 의하여 제조된 본 발명의 피부유래 유산균인 HK-9을 이용한 산사 발효 추출물을 함유하는 마사지크림을 제조하였다.
A massaging cream containing an acid-fast-fermented extract of HK-9, which is a skin-derived lactic acid bacterium of the present invention prepared by a conventional method for producing a massage cream, was prepared as shown in Table 5 below.
<2-5> <2-5> 팩pack
하기 표 6과 같은 조성으로 통상적인 팩 제조방법에 의하여 제조된 본 발명의 피부유래 유산균인 HK-9을 이용한 산사 발효 추출물을 함유하는 팩을 제조하였다.
A pack containing the fermented sea tangle extract of HK-9, which is the skin-derived lactic acid bacterium of the present invention prepared by a conventional pack preparation method, was prepared as shown in Table 6 below.
<< 실험예Experimental Example 1> 1>
산사 발효 추출물의 피부 세포 증식 효과 확인Confirmation of skin cell proliferation effect of Sansa fermented extract
본 발명의 방법으로 제조된 산사 발효 추출물에 피부 세포 증식 효과가 있는지 여부를 알아보기 위하여 인체 정상 섬유아세포(한국세포주은행)를 96-웰 마이크로 플레이트(96-well microplate)의 각 웰에 1 x 104 세포가 되도록 접종하고, RPMI1640 배지(Sigma사)에서 24시간 동안 37℃에서 배양하였다. 이어, 상기 산사 발효 추출물이 농도 0.5%, 1%로 포함된 혈청이 없는 RPMI1640 배지로 교체한 실험군과 산사 발효 추출물이 포함되지 않은 혈청이 없는 RPMI1640 배지로 교체한 대조군을 24시간 동안 추가로 배양하였다. To investigate the effect of the present invention on the skin cell proliferation effect, human normal fibroblast (Korean Cell Line Bank) was added to each well of a 96-well microplate at 1 x 10 < 4 cells, and cultured in RPMI1640 medium (Sigma) for 24 hours at 37 占 폚. Then, the control group was replaced with the serum-free RPMI1640 medium containing 0.5% and 1% of the acid fermentation extract and the serum-free RPMI1640 medium without the fermentation extract of Sansafura, and further cultured for 24 hours .
그런 다음, MTT 용액(3-(4,5-디메틸티아졸-2-일) 2,5-디페닐테트라졸륨 브로마이드: 5mg/㎖)을 각각 10㎕씩 첨가하고, 4시간 동안 배양한 후, 배지를 제거하고, 각 웰당 100㎕의 DMSO 용액을 가하여 20분 동안 진탕시키고, 마이크로 플레이트 판독기(microplate reader, Molecular Devices, USA)를 이용하여 517nm에서 상층액의 흡광도를 측정하였다. 측정값을 하기의 수학식 1에 대입하여 세포 증식 효과를 산출하고, 그 결과는 표 7에 나타내었다.
Then, 10 μl each of the MTT solution (3- (4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide: 5 mg / ml) was added and cultured for 4 hours, The medium was removed, 100 μl of DMSO solution was added to each well, shaken for 20 minutes, and the absorbance of the supernatant was measured at 517 nm using a microplate reader (Molecular Devices, USA). The cell proliferation effect was calculated by substituting the measurement value into the following equation (1), and the results are shown in Table 7.
[수학식 1][Equation 1]
세포증식효과(%) = [(실험군 흡광도 - 대조군의 흡광도)/대조군의 흡광도] × 100
Cell proliferation effect (%) = [(absorbance of test group - absorbance of control group) / absorbance of control group] × 100
상기 표 7에서 알 수 있듯이, 산사 발효 추출물을 처리하지 않은 대조군과 비교하여, 산사 발효 추출물 모든 실험군에서 60% 이상의 높은 섬유아세포 증식 효과를 나타냈으며 그 중 피부유래 유산균인 HK-9을 이용한 산사 발효추출물이 80.9%의 가장 높은 증식 효과를 나타내었다.
As can be seen from Table 7 above, compared with the control group not treated with the fermented sea urchin fermented extract, all the experimental groups of the fermented sea urchin fermented extract showed a high proliferation effect of 60% or more. Among them, the fermented soybean fermented with HK-9 The extract showed the highest proliferation effect of 80.9%.
<< 실험예Experimental Example 2> 2>
산사 발효 추출물의 항산화 효과 확인Identification of Antioxidative Effect of Sansa Fermented Extract
본 발명자들은 산사 발효 추출물의 항산화 활성 검증을 위해 DPPH (1,1-diphenyl-2-picrylhydrazyl) 라디칼 소거능 측정을 하였다. The present inventors measured DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity to examine the antioxidative activity of the fermented extract of Sasa sp.
DPPH 라디칼 소거능 측정법은 항산화 활성 측정 실험 중 하나이며, 항산화질의 전자공여능으로 인해 방향족 화합물 및 방향족 아민류에 의해 환원되어 자색이 탈색되는 정도를 나타내는 정도를 지표로 하여 항산화능을 측정하는 방법이다. The DPPH radical scavenging assay is one of the experiments for measuring antioxidant activity and is a method for measuring antioxidant activity by using the degree of depigmentation of purple color as an index as reduced by aromatic compounds and aromatic amines due to the electron donating ability of the antioxidants.
이를 위하여, 본 발명의 산사 발효 추출물을 에탄올에 녹여 농도별로 2 mL를 제조하여 200 μM의 DPPH 용액 1 mL를 첨가하였다. 반응액을 완전히 섞기 위해서 10초간 볼텍싱(vortexing)한 다음, 실온에서 30분간 반응시켰다. 남아있는 DPPH의 양을 측정하기 위해서 UV-vis 분광광도계(852A Diode Array Spectrophotometer, Hewlett Packard)를 이용하여 517㎚에서 흡광도를 측정하여 그 결과를 도 1에 나타내었다. To this end, 2 μL of the granular extract of the present invention was dissolved in ethanol to prepare 2 mL of each concentration, and 1 mL of 200 μM DPPH solution was added. The reaction solution was vortexed for 10 seconds to mix thoroughly, and then allowed to react at room temperature for 30 minutes. The absorbance was measured at 517 nm using a UV-vis spectrophotometer (852A Diode Array Spectrophotometer, Hewlett Packard) to measure the amount of DPPH remaining. The results are shown in FIG.
그 결과, 산사 발효 추출물 모두에서 농도가 증가할수록 DPPH 라디칼 소거능 수치가 증가하는 경향을 나타냈으며, 최고 농도인 1000㎍/ml의 농도에서 70% 이상의 높은 소거능을 나타내었다. 그 중 피부유래 유산균인 HK-9을 이용한 본 발명의 산사 발효 추출물의 소거능은 93.19%로 나타나 항산화 활성이 탁월하다는 것을 알 수 있었다(도 1 참조).
As a result, the DPPH radical scavenging ability tended to increase with increasing concentration in all the fermented sea urchin extracts, and showed a high sorption capacity over 70% at the highest concentration of 1000 μg / ml. The scavenging ability of the present invention using the skin-derived lactic acid bacterium HK-9 was 93.19%, indicating that the antioxidative activity was excellent (see FIG. 1).
<< 실험예Experimental Example 3> 3>
산사 발효 추출물의 보습 효과 확인Identification of moisturizing effect of Sansa fermented extract
본 발명자들은 산사 발효 추출물에 보습 효과가 있는지를 알아보기 위해 Collagen type I 생성량을 측정하였다. The present inventors measured the amount of collagen type I produced in order to investigate the moisturizing effect of the fermented sea urchin extract.
이를 위하여 0.2% DMSO를 음성대조군으로, 0.2 mM 아스코르브산(ascorbic acid)을 양성 대조군으로 사용하였으며, 시험물질의 농도는 0.2, 0.4, 0.6, 0.8, 1.0 mg/mL로 각각 조제하였다. 배양된 사람의 섬유아세포(human fibroblast)인 CCD-986sk를 96 well pate에 2×104 cells/well로 분주하여 24시간 동안 배양한 세포들을 serum-free DMEM으로 3회 세척하고, 산사 발효 추출물을 농도별로 녹인 DMEM용액에 10% FBS를 첨가하여 다시 24시간 배양하였다. 배양액으로부터 생성된 procollagen type I C-peptide를 enzyme-linked immunosorbent assay kit(Takara Bio Inc.,Otsu, Japan)을 이용하여 정량하였다.For this purpose, 0.2% DMSO was used as a negative control, 0.2 mM ascorbic acid was used as a positive control, and test substance concentrations were adjusted to 0.2, 0.4, 0.6, 0.8 and 1.0 mg / mL, respectively. The cultured human fibroblast CCD-986sk was dispensed in 96 well pellet at 2 × 10 4 cells / well. Cells cultured for 24 hours were washed three times with serum-free DMEM, 10% FBS was added to the DMEM solution, which was dissolved in each concentration, and the cells were further cultured for 24 hours. Procollagen type I C-peptide was quantitated using an enzyme-linked immunosorbent assay kit (Takara Bio Inc., Otsu, Japan).
표 8은 CCD-986sk 세포 증식에 따른 산사 발효 추출물의 콜라겐 합성능에 대한 결과를 나타낸 것이다.
Table 8 shows the results of the collagen synthesis performance of the acid-fast fermented extract according to CCD-986sk cell proliferation.
산사 발효 추출물과 양성 대조군인 아스코르브산의 콜라겐 합성능을 비교한 결과, 산사 발효 추출물의 첨가를 통해 모든 조건의 콜라겐 생성량이 농도 의존적으로 증가하는 경향을 나타내었으며, 1.0 mg/mL의 양성 대조군에 비해 높은 콜라겐 합성량을 나타냄을 알 수 있었다(표 8 참조).As a result of comparing the collagen synthesis performance of the acid fermentation extract and ascorbic acid as a positive control, the collagen production amount in all conditions tended to increase in a concentration dependent manner by adding the fermented extract of Sasa japonica, and compared with the positive control group of 1.0 mg / mL And high collagen amount (see Table 8).
한편, 콜라겐 층은 교원질 분해 효소(collagenase) 이외의 효소작용을 받지 않으며 방수력, 보습, 탄력 유지 등 피부건강에 중요한 역할을 담당함에 따라 본 발명 콜라겐의 합성 촉진 결과는 피부 면역 및 보습력에 도움이 되는 것으로 나타났다.
On the other hand, since the collagen layer does not undergo an enzyme action other than collagenase and plays an important role in skin health such as waterproofing, moisturizing and elasticity maintenance, the result of stimulating the synthesis of collagen of the present invention is effective for skin immunity and moisturizing Respectively.
<< 실험예Experimental Example 4> 4>
산사 발효 추출물의 주름 억제 효과 측정Measurement of wrinkle inhibition effect of Sansa fermented extract
본 발명의 산사 발효 추출물에 주름을 억제하는 효과가 있는지를 알아보기 위하여 하기와 같이 실험을 진행하였다. Experiments were carried out as follows to investigate whether wrinkle suppression effect of the present invention was inhibited.
먼저, 사람의 섬유아세포(human fibroblast)인 CCD-986sk를 1.5 x 105 cells/mL의 농도로 35 mm dish에 약 80%의 confluency에 도달할 때까지 배양하였다. UV 조사 건에 배지를 제거한 후 PBS(phosphate buffered saline)로 세척하여 배지 내 혈청(serum) 성분을 제거한 다음, LUX metter (DM-28, Takemura, Japan)을 이용하여 6.3 J/cm2으로 맞추어 조사하였다. UVA 조사 후 배양 배지는 FBS를 첨가하지 않은 DMEM 배지에 분자량별로 모아진 분획물을 1 mg/mL의 농도로 투여하여 24시간 동안 배양하였다. First, a human fibroblast, CCD-986sk, was cultured in a 35 mm dish at a concentration of 1.5 x 10 5 cells / mL until a confluency of about 80% was reached. After the medium was removed from the UV irradiation, the serum was removed from the medium by washing with PBS (phosphate buffered saline), and the medium was adjusted to 6.3 J / cm 2 using LUX metter (DM-28, Takemura, Japan) Respectively. After UVA irradiation, the fraction collected by molecular weight was added to DMEM medium without FBS at a concentration of 1 mg / mL for 24 hours.
UVA 조사에 의해 유도되는 MMP-1 발현량 측정은 Dunsmore등이 사용한 방법을 실시하였다. UVA를 조사 후 산사 발효 추출물을 처리하여 24시간 동안 코팅(coating)하였다. TBS (phosphate buffered saline + 0.05% Tween 20)로 3회 세척하고 3% PBS로 37℃에서 1시간 동안 블락킹(blocking)한 후, 1차 항체 (monoclonal anti-MMP-1)를 블락킹 버퍼(blocking buffer)로 1:3,000으로 희석하여 처리하고 37℃에서 90분간 반응시켰다. PBS로 세척한 다음 2차 항체(alkaline phosphatase conjugated goat anti-mouse IgG)를 블락킹 버퍼에 1:3,000으로 희석하여 처리하고, 37℃에서 90분간 반응시킨 후 PBS로 세척한 다음 알칼리포스파타제(alkaline phosphatase) 기질 용액(1 mg/mL, p-nitrophenyl phosphate in diethanolamine buffer)을 첨가하여 실온에서 30분간 반응 시켰다. 3 N NaOH로 반응을 완전히 중지시킨 후 흡광기(microplate reader)를 이용하여 405 nm에서 흡광도를 측정하였다.The amount of MMP-1 expression induced by UVA irradiation was measured by Dunsmore et al. After irradiation with UVA, the fermented extract was treated for 24 hours. After washing three times with TBS (phosphate buffered saline + 0.05% Tween 20) and blocking with 3% PBS at 37 ° C for 1 hour, the monoclonal anti-MMP-1 was blocked with Blocking buffer blocking buffer) at a ratio of 1: 3,000, followed by reaction at 37 ° C for 90 minutes. After washing with PBS, the secondary antibody (alkaline phosphatase conjugated goat anti-mouse IgG) was diluted 1: 3,000 in Blocking buffer, incubated at 37 ° C for 90 minutes, washed with PBS and incubated with alkaline phosphatase ) Substrate solution (1 mg / mL, p-nitrophenyl phosphate in diethanolamine buffer) was added and reacted at room temperature for 30 minutes. The reaction was stopped completely with 3 N NaOH and absorbance was measured at 405 nm using a microplate reader.
피부의 광노화에 의한 피부주름생성에 중요한 역할을 담당하고 있는 MMP-1의 발현은 UVA에 의해 세포에서 JNK/p38 활성도가 증가하고 전사인자인 AP-1의 활성도가 증가되는 신호전달 경로를 통해 MMP-1 발현을 증가시켜 피부에서 교원질의 결핍을 초래한다고 알려져 있다. 이러한 UVA에 의해 발현이 증가되는 MMP-1에 미치는 산사 발효 추출물의 영향을 알아보고자 HDFs에 UVA를 조사하고 산사 발효 추출물을 첨가하여 24시간 동안 배양한 후 MMP-1 발현 저해 효과를 ELISA로 측정히였다. The expression of MMP-1, which plays an important role in skin wrinkle formation due to photoaging of skin, is induced by UVA to increase JNK / p38 activity and increase the activity of AP-1, a transcription factor, -1 expression, leading to a deficiency of collagen in the skin. In order to investigate the effect of the fermented extract on the growth of MMP-1 induced by UVA, UVA was irradiated on HDFs, and the culture inhibitor of MMP-1 was cultured for 24 hours after the addition of the fermentation extract Respectively.
그 결과, 산사 발효 추출물에서 농도 의존적으로 MMP-1 발현 저해율이 높아져 최고 농도인 1 mg/mL에서 산사 발효 추출물을 대조군과 비교하여 각각 일반 산사 추출물은 60.15%, HK-9를 이용한 산사 발효 추출물은 69.55%, L. bulgaricus를 이용한 산사 발효 추출물은 64.02%, B. longum을 이용한 산사 발효 추출물은 35.81%의 저해율을 나타낸 것으로 보아 MMP-1의 발현을 효과적으로 조절하여 주름 발현을 저해함을 알 수 있었다(도 2 참조).
As a result, the inhibition rate of MMP-1 expression was increased in a concentration-dependent manner in the fermented sea tangle fermentation extract, and compared with the control fermented sea tangle extract at the highest concentration of 1 mg / mL, 60.15% 69.55%, and L. bulgaricus showed 64.02% inhibition rate and 35.81% inhibition rate, respectively, of B. longum. Thus, it was found that the expression of MMP-1 effectively inhibited wrinkle expression (See Fig. 2).
<< 실험예Experimental Example 5> 5>
산사 발효 추출물의 피부 미백 효과 측정Measurement of skin whitening effect of Sansa fermented extract
본 발명의 산사 발효 추출물에 피부 미백 효과가 있는지를 알아보기 위하여 멜라닌을 생성하는 쥐 유래 멜라노사이트(melanocyte)인 Clone-M3를 이용하여 멜라닌 생성량을 측정하였다. Melanin production was measured by using mouse-derived melanocyte Clone-M3, which produces melanin, in order to examine whether the extract of the present invention has skin whitening effect.
먼저, Clone-M3를 96웰에 접종하고 24시간 후에 3일간 각 시료를 3일동안 처리하였다. 3일 후에 각 웰의 배지를 제거한 후에 PBS로 세척하고, 각 웰 당 1 ㎖의 1N NaOH를 가한 다음 교반시켜 멜라닌 성분이 용출되도록 하였다. 용출된 멜라닌의 함량을 측정하기 위하여 흡광기를 이용하여 400 ㎚에서 흡광도를 측정하였다. First, Clone-M3 was inoculated in 96 wells, and after 24 hours, each sample was treated for 3 days for 3 days. After 3 days, the medium of each well was removed, followed by washing with PBS. 1 ml of 1N NaOH was added to each well, followed by stirring to allow the melanin component to elute. Absorbance was measured at 400 nm using a light absorber to measure the content of eluted melanin.
양성대조군으로는 멜라솔브(melasolv)를 사용하였으며 최고농도인 100 ㎍/㎖으로 처리하여 측정하였다.As a positive control, melasolv was used, and the treatment was carried out at a maximum concentration of 100 μg / ml.
그 결과, 농도가 증가할수록 멜라닌 합성 저해율이 높아지는 것을 확인할 수 있었으며, 최고농도인 100 ㎍/㎖에서 각각 일반 산사 추출물은 34.11%, HK-9를 이용한 산사 발효 추출물은 41.21%, L. bulgaricus를 이용한 산사 발효 추출물은 35.87%, B. longum을 이용한 산사 발효 추출물은 36.99%로 나타났다(도 3 참조).As a result, it was confirmed that the inhibition rate of melanin synthesis was increased as the concentration was increased. In the highest concentration of 100 ㎍ / ㎖, 34.11% of general crustacean extract, 41.21% of Crassulaceae fermentation extract using HK-9, and L. bulgaricus 35.87% of the fermented mushroom extract and 36.99% of the fermented mushroom extract using B. longum (see FIG. 3).
상기 산사 발효 추출물은 양성대조군인 멜라솔브의 멜라닌 합성 저해율과 비교하였을 때 비슷한 수치를 나타내는 것으로 보아 뛰어난 미백활성이 있음을 알 수 있었다.
The above fermented extracts showed similar values when compared with the melanin synthesis inhibitory rate of the positive control group melasolve, indicating that there is an excellent whitening activity.
<< 실험예Experimental Example 6> 6>
산사 발효 추출물의 피부 항염 효과 측정Measurement of skin anti-inflammatory effect of Sansa fermented extract
본 발명의 산사 발효 추출물에 항염 활성이 있는지를 확인하기 위하여 마크로파지(Macrophage)를 이용하여 nitric oxide(NO) 생성량 측정하였다.The amount of nitric oxide (NO) production was measured using Macrophage in order to confirm the anti-inflammatory activity of the present invention.
NO 생성량 측정을 위해 사용된 세포주는 마우스 유래 J774.1 대식세포를 사용하였으며, 세포를 10% FBS와 RPMI 1640 배지에 배양하여 24웰 플레이트(well plate)에 4.5×10⁴ cells/well의 농도로 넣은 다음, 시료를 첨가한 것과 첨가하지 않은 두 가지 군을 나누어 모두 37℃, 5% CO2 배양기에 48시간 동안 배양한 후 LPS (lipipilysaccharide)를 200 ng/well의 농도로 처리하여 48시간 동안 세포를 배양하였다. 상등액 50 μg을 취하여 동일 부피의 Griess시약(1% sulfanilamide/0.1% N-(1-naphthyl)-ethylenediamine dihtdrochloride/2.5% h3po4)을 첨가하여 실온에서 10분간 반응시킨 후, 흡광기를 이용하여 540 nm의 흡광도를 측정하였다. 아질산염(Nitrite)의 표준물질로는 아질산나트륨(sodium nitrite)을 사용하였으며, 농도는 32 μM에서부터 0.25 μM까지 RPMI 1640 배지로 2배씩 희석하여 얻은 표준곡선과 비교하여 계산하였다.The cell lines used for measuring the amount of NO production were mouse-derived J774.1 macrophages. The cells were cultured in 10% FBS and RPMI 1640 medium and placed in a 24-well plate at a concentration of 4.5 x 10 4 cells / well Then, the cells were cultured in a 5% CO2 incubator at 37 ° C for 48 hours. LPS (lipipilysaccharide) was treated at a concentration of 200 ng / well, and the cells were cultured for 48 hours Respectively. 50 μg of the supernatant was added and the same volume of Griess reagent (1% sulfanilamide / 0.1% N- (1-naphthyl) -ethylenediamine dihydrochloride / 2.5% h3po4) was added and reacted at room temperature for 10 minutes. Was measured. Sodium nitrite was used as a standard for nitrite, and the concentration was calculated by comparing the standard curve obtained by doubling the concentration from 32 μM to 0.25 μM in RPMI 1640 medium.
도 4는 산사 발효 추출물의 항염 효능을 측정한 실험결과로 대식세포의 NOS (nitric oxide synthase)는 TNF-γ, TNF-α와 같은 여러 가지 사이토카인이나 LPS (E. coli 유래 lipopolysaccharide) 등 세균내독소의 영향을 받아 NOS 유전자가 발현 유도됨으로써 나타나기 때문에 이를 확인하고자 시료와 LPS를 단독 및 함께 투여함으로써 NO의 생성능을 확인하였다. FIG. 4 is a graph showing the results of the measurement of the anti-inflammatory activity of the acid fermentation extract. As a result, the NOS (nitric oxide synthase) of macrophages was expressed in various bacteria such as TNF-γ and TNF- α and lipopolysaccharide Since the NOS gene is induced by the influence of the toxin, the NO production ability was confirmed by administering the sample and LPS alone or together in order to confirm this.
그 결과, 시료를 단독 투여한 경우 대조군과 비교하여 큰 차이를 보이지 않았으나 LPS와 함께 처리할 경우, LPS를 단독으로 처리한 4.2 μM보다, 월등히 높은 NO 생성량을 보이며, 특히 피부유래 유산균인 HK-9을 이용한 본 발명의 산사 발효 추출물의 경우 10.5 μM로써 높은 NO 생성량을 보여 뛰어난 항염 활성을 보임을 알 수 있었다(도 4 참조).
As a result, no significant difference was observed in the case of administration of the sample alone compared with the control group. However, the treatment with LPS showed significantly higher NO production than 4.2 μM treated with LPS alone, (10.5 [mu] M) of the present invention showed an excellent anti-inflammatory activity (see FIG. 4).
<< 실험예Experimental Example 7> 7>
산사 발효 추출물의 피부 안정성 확인 시험Test for skin stability of Sansa fermented extract
본 발명의 산사 발효 추출물의 피부 안정성 유무를 확인하기 위하여 하기와 같이 실험을 진행하였다. In order to confirm the skin stability of the granular extract of the present invention, the following experiment was carried out.
먼저, 20-30대의 남녀 각각 10명씩을 대상으로 피부를 깨끗한 물로 세척한 것을 대조군으로 하여, 실시예 1의 산사 발효 추출물을 1%로 희석한 희석액 및 덱사메타존 연고를 피부에 도포한 후, 자외선(100mJ/㎠)을 조사(照射)하였다. 7일까지 매일 한번 씩 상기 물질들을 피부에 도포하였으며 조사 전과 조사 후 멕사미터(Mexameter)로 홍반지수를 측정하여 평균값을 나타내었다.
First, the skin was washed with clean water for 10 persons in each of 20 to 30 male and female subjects, and the diluted solution of 1% of the crude extract of Example 1 and the dexamethasone ointment of Example 1 were applied to the skin, And irradiated with ultraviolet rays (100 mJ / cm 2). The above materials were applied to the skin once every day until day 7 and the average value was measured before and after the irradiation by measuring the erythema index with Mexameter.
표 9에서 보는 바와 같이, 본 발명의 방법으로 제조된 산사 발효 추출물에서 피부 자극 보호 효과를 보임을 알 수 있었으며, 양성대조군으로 실험한 덱사메타존과 비슷한 효과를 나태낸 것으로 보아 피부 보호 효과가 우수함을 확인할 수 있었다(표 9 참조).
As shown in Table 9, it was found that the extract of Sansafura fermented by the method of the present invention shows a protective effect against skin irritation and has a similar effect to that of dexamethasone tested as a positive control. (See Table 9).
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (11)
(b) 상기 (a)단계에서 얻어진 유산균이 배양된 배지에 건조된 산사와 배양 배지의 양을 전체 배양배지 중량 대비 1:8 ~ 1:12의 비율로 혐기 배양하여 산사의 발효물을 제조하는 단계;
(c) 상기 (b)단계에서 얻어진 산사의 발효액을 따로 모아두고 남은 건체 산사의 발효물을 전체 배양배지 중량 대비 1:8 ~ 1:12의 비율로 준비하고, 70% 에탄올을 이용하여 50 ~ 70℃의 온도에서 20 ~ 28시간동안 진탕추출을 한 후 추출물을 여과지로 여과하여 산사의 추출물을 제조하는 단계; 및
(d) 상기 (b)단계에서 얻어진 산사의 발효물과 (c)단계에서 얻어진 산사의 추출물을 혼합하는 단계;를 포함하는 산사 발효 추출물 제조방법.(a) inoculating lactic acid bacteria into a medium sterilized by a high-pressure sterilizer at a concentration of 3 to 7% (v / v) and anaerobically culturing at a temperature of 34 to 40 ° C for 12 to 36 hours;
(b) anaerobically culturing the cultured suspension of the lactic acid bacteria obtained in step (a) at a ratio of 1: 8 to 1:12 based on the total culture medium weight to produce a fermented product step;
(c) The fermented broodstock fermented from the step (b) is separately collected, and the remaining fermented broodstock is prepared at a ratio of 1: 8 to 1:12 with respect to the total culture medium weight. Extracting the extract with shaking at a temperature of 70 ° C for 20 to 28 hours, filtering the extract with a filter paper to prepare an extract of Acanthopanax senticosus; And
(d) mixing the fermented product of the horse mackerel obtained in the step (b) with the extract of the horse mackerel obtained in the step (c).
상기 (a)단계의 유산균은 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)로 이루어진 군에서 선택된 1종 이상인 것을 특징으로 하는 산사 발효 추출물 제조방법.The method according to claim 1,
The (a) step of the lactic acid bacteria is Lactobacillus ramno suspension HK-9 (Lactobacillus Ramnosus HK-9) KCCM11254P, Lactobacillus ( Lactobacillus acidophilus , and Lactobacillus bulgaricus. < RTI ID = 0.0 > 21. < / RTI >
상기 산사 발효 추출물은 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)로 이루어진 군에서 선택된 1종 이상의 유산균으로 발효된 것을 특징으로 하는 피부 노화 방지용 화장료 조성물.5. The method of claim 4,
The above fermented sea tangle extract contains Lactobacillus Lambosus HK-9 ( Lactobacillus Ramnosus HK-9) KCCM11254P, Lactobacillus ( Lactobacillus acidophilus , and Lactobacillus bulgaricus . The composition for preventing skin aging according to claim 1, wherein the composition is fermented with at least one lactic acid bacterium selected from the group consisting of Lactobacillus acidophilus and Lactobacillus bulgaricus .
상기 산사 발효 추출물은 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)로 이루어진 군에서 선택된 1종 이상의 유산균으로 발효된 것을 특징으로 하는 피부 미백용 화장료 조성물.The method according to claim 6,
The above fermented sea tangle extract contains Lactobacillus Lambosus HK-9 ( Lactobacillus Ramnosus HK-9) KCCM11254P, Lactobacillus ( Lactobacillus acidophilus , and Lactobacillus bulgaricus . The cosmetic composition for skin whitening according to claim 1, wherein the composition is fermented with at least one lactic acid bacterium selected from the group consisting of Lactobacillus acidophilus and Lactobacillus bulgaricus .
상기 산사 발효 추출물은 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)로 이루어진 군에서 선택된 1종 이상의 유산균으로 발효된 것을 특징으로 하는 피부 미백용 화장료 조성물.9. The method of claim 8,
The above fermented sea tangle extract contains Lactobacillus Lambosus HK-9 ( Lactobacillus Ramnosus HK-9) KCCM11254P, Lactobacillus ( Lactobacillus acidophilus , and Lactobacillus bulgaricus . The cosmetic composition for skin whitening according to claim 1, wherein the composition is fermented with at least one lactic acid bacterium selected from the group consisting of Lactobacillus acidophilus and Lactobacillus bulgaricus .
상기 산사 발효 추출물은 락토바실러스 람노서스 HK-9(Lactobacillus Ramnosus HK-9) KCCM11254P, 락토바실러스 에시도필러스(Lactobacillus acidophilus) 및 락토바실러스 불가리커스(Lactobacillus bulgaricus)로 이루어진 군에서 선택된 1종 이상의 유산균으로 발효된 것을 특징으로 하는 피부 미백용 화장료 조성물.11. The method of claim 10,
The above-mentioned fermented sea tangle fermented extract was prepared by mixing Lactobacillus Ramnosus HK-9 KCCM11254P, Lactobacillus acidophilus , and Lactobacillus bulgaricus . The cosmetic composition for skin whitening according to claim 1, wherein the composition is fermented with at least one lactic acid bacterium selected from the group consisting of Lactobacillus acidophilus and Lactobacillus bulgaricus .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140182953A KR20160074116A (en) | 2014-12-18 | 2014-12-18 | Cosmetic composition containing Crataegis fructus fermented extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140182953A KR20160074116A (en) | 2014-12-18 | 2014-12-18 | Cosmetic composition containing Crataegis fructus fermented extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160074116A true KR20160074116A (en) | 2016-06-28 |
Family
ID=56366111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140182953A Ceased KR20160074116A (en) | 2014-12-18 | 2014-12-18 | Cosmetic composition containing Crataegis fructus fermented extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160074116A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102152878B1 (en) * | 2020-03-02 | 2020-09-07 | 주식회사 잇츠한불 | Lactobacillus pentosus strain and composition for improving microbial flora and improving skin varrier comprising the same |
| CN113398174A (en) * | 2021-05-24 | 2021-09-17 | 深圳海创生物科技有限公司 | Traditional Chinese medicine probiotic fermentation product, compound and composition and application thereof in preparation of product with anti-helicobacter pylori effect |
| CN114588091A (en) * | 2022-04-21 | 2022-06-07 | 加来(济南)生活科技有限公司 | Preparation method of Hami melon fermentation raw pulp and application of Hami melon fermentation raw pulp in cosmetics |
| CN116585277A (en) * | 2023-05-06 | 2023-08-15 | 金木集团有限公司 | A kind of coenzyme Q10 chewable tablet and preparation method thereof |
| KR102567315B1 (en) * | 2022-12-29 | 2023-08-17 | (주)예그리나 | Cosmetic composition for gray hair containing fermented extracts of natural ingredients |
| KR102585337B1 (en) * | 2022-10-13 | 2023-10-10 | 록야 주식회사 | Manufacturing method of postbiotics using Lactobacillus rhamnosus B3421 isolated from ginseng sprout and composition comprising the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110057954A (en) | 2009-11-25 | 2011-06-01 | (주)아모레퍼시픽 | Antioxidant or anti-aging cosmetic composition |
-
2014
- 2014-12-18 KR KR1020140182953A patent/KR20160074116A/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110057954A (en) | 2009-11-25 | 2011-06-01 | (주)아모레퍼시픽 | Antioxidant or anti-aging cosmetic composition |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102152878B1 (en) * | 2020-03-02 | 2020-09-07 | 주식회사 잇츠한불 | Lactobacillus pentosus strain and composition for improving microbial flora and improving skin varrier comprising the same |
| CN113398174A (en) * | 2021-05-24 | 2021-09-17 | 深圳海创生物科技有限公司 | Traditional Chinese medicine probiotic fermentation product, compound and composition and application thereof in preparation of product with anti-helicobacter pylori effect |
| CN114588091A (en) * | 2022-04-21 | 2022-06-07 | 加来(济南)生活科技有限公司 | Preparation method of Hami melon fermentation raw pulp and application of Hami melon fermentation raw pulp in cosmetics |
| CN114588091B (en) * | 2022-04-21 | 2023-09-26 | 加来(济南)生活科技有限公司 | Preparation method of cantaloupe fermentation primary pulp and application of cantaloupe fermentation primary pulp in cosmetics |
| KR102585337B1 (en) * | 2022-10-13 | 2023-10-10 | 록야 주식회사 | Manufacturing method of postbiotics using Lactobacillus rhamnosus B3421 isolated from ginseng sprout and composition comprising the same |
| KR102567315B1 (en) * | 2022-12-29 | 2023-08-17 | (주)예그리나 | Cosmetic composition for gray hair containing fermented extracts of natural ingredients |
| CN116585277A (en) * | 2023-05-06 | 2023-08-15 | 金木集团有限公司 | A kind of coenzyme Q10 chewable tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101627850B1 (en) | Method of fermentation using complex strains and cosmetic composition comprising thereof | |
| KR101770140B1 (en) | Lactobacillus fermentum HK and Phormium tenax Fermented extract Manufactured Using Thereof | |
| KR102553057B1 (en) | Compositions comprising skin derived lactic acid bacteria having effects of anti-oxidation, anti-inflammation and whitening | |
| KR101452770B1 (en) | Cosmetic composition comprising lactobacillus fermented solution having anti-oxidation, whitening and anti-wrinkle effect | |
| KR102194315B1 (en) | Antioxidant or skin microbiome balance cosmetic composition comprising centella asiatica fermented extract fermented by inoculating lactobacillus rhamnosus strain | |
| KR101229045B1 (en) | Extracting method of nelumbo nucifera flower, leaf, stem, root, seed and cosmetic composition for anti-wrinkle containing extracts thereby | |
| KR20160074116A (en) | Cosmetic composition containing Crataegis fructus fermented extract | |
| CN114085787B (en) | Novel lactobacillus strains and uses thereof | |
| KR101875001B1 (en) | Lactobacillus fermentum GFCSJ and cacao nibs Fermented extract Manufactured Using Thereof | |
| KR102618301B1 (en) | Cosmetic composition comprising probiotics culture | |
| CN108042456B (en) | Preparation method and application of dendrobium officinale fermentation product | |
| KR101914344B1 (en) | A moisturizing and anti-wrinkle cosmetic composition comprising fermented barley, fermented pear juice, fermented soybeans and fermented pomegranate extract and the method preparation of thereof | |
| KR100843745B1 (en) | Spirulina fermented extract and preparation method thereof | |
| KR102247810B1 (en) | Composition Comprising Mixed Culture Strain of Lactobacillus sp. SDCM 1003 and SDCM 1105, Culture Fluid, or Culture Fluid Extract thereof as Active Ingredient | |
| KR102244812B1 (en) | Composition Comprising Mixed Culture Strain of Lactobacillus plantarum subsp. plantarum SDCM 1002 and Saccharomyce cerevisiae SDCM 3017, Culture Fluid, or Culture Fluid Extract thereof as Active Ingredient | |
| KR101810141B1 (en) | Lactobacillus plantarum HK and Telopea speciosissima Fermented extract Manufactured Using Thereof | |
| KR101819060B1 (en) | Cosmetic Compositions Containing Fermented Extracts of Hwangryunhaedoktang | |
| JP2017055665A (en) | Method for producing useful product | |
| KR101292944B1 (en) | skin-whitening, anti-bacterial and anti-inflammatory composition comprising a fermented juice of grape | |
| KR101796955B1 (en) | Cosmetic Composition Comprising the Extract of Mixed Fermentation with Sanguisorba Officinalis and Piper Longum Linn. showing Skin Anti-Aging and Whitening Effect, a preparation method thereof | |
| KR102355138B1 (en) | Composition for whitening or anti-wrinkle of the skin comprising fermentated ziziphus jujuba seed as effective component | |
| KR101429117B1 (en) | Composition for skin-whitening comprising extract of calyx of peach blossom | |
| KR20190023496A (en) | Process for producing fermented algae containing fucose and a cosmetic composition containing the same | |
| KR20220116780A (en) | Manufacturing method for skin whitening composition using Rosa multiflora | |
| KR102453568B1 (en) | Composition for moisturizing and anti-inflammation comprising fermented Codium fragile extract fermented by inoculating Bacillus safensis strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20141218 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160504 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20160708 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20160504 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |